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performed in our center. A total of 22 patients (14%) under-
went 24 TJLB procedures at a median of 38 days (12-152)
after transplant. Median age was 29 years (range 17-64).
Most patients receivedmyeloablative allo-SCT (n¼18)mainly
for AML (n¼6). Transjugular route was chosen because of
thrombocytopenia (n¼12, 50%), coagulation abnormalities
(n¼2, 8.3%) or both (n¼10, 41%). Clinical suspicions before
TJLB were hepatic sinusoidal obstructive syndrome (SOS)
(n¼12, 50%) and GVHD (n¼12, 50%). The biopsy allowed
a diagnosis in 17 cases (70%) including: iron overload/
cholestatic liver disease (n¼8), liver GVHD (n¼4), HSOS
(n¼3), and one case each of cholangitis lenta and CMV
hepatitis (n¼2). Main clinical suspicion was conﬁrmed after
biopsy in 5 (21%) cases while in 12 (50%) it revealed another
initial diagnosis suspected and supposed a change of thera-
peutic approach in 8 (33%) of them. Seven (29%) biopsies
were non-diagnostic, 5 due to unspeciﬁc ﬁndings and 2
because of insufﬁcient sample size. Although commonly
TJLB-related complications were mild, mainly subcutaneous
hematoma (n¼3, 12.5%) there also was one TJLB-related
death because of severe bleeding. In summary, TJLB allowed
for the identiﬁcation of a cause of liver abnormality in 70% of
our patients, including 33% in which the diagnosis implied
a change in the therapy. It may be a helpful tool in the
diagnosis of liver abnormalities, with moderate toxicity but
not risk-free.349
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Background: Hemophagocytic lymphohistiocytosis (HLH),
a group of immunodeﬁciency disorder characterized by
defective lymphocyte cytotoxicity and immune dysregula-
tion leading to hyper inﬂammatory state. If untreated, this
condition is potentially fatal. Currently, allogeneic hemato-
poietic cell transplantation (HCT) is the only deﬁnitive
curative therapy for HLH. Recently, with increased aware-
ness, HLH is being diagnosed in adults. However, there is
very limited data on HCT outcome for adults with HLH. Here
we report our experience of allogeneic HCT for HLH in adults
(18 years).
Methods: We retrospectively analyzed the outcomes of 10
adult patients with HLH (7 male and 3 female) who had
undergone allogeneic HCT between January 2004 and
September 2012 in our institution. Genetic diagnosis was
made in 4 patients (2 perforin defect, one MUNC 13-4, one
XIAP). CNS involvement at diagnosis was noted in 5 patients,
all of them received some form of induction therapy based
on HLH-2004 protocol, and at the time of transplant HLHwas
well controlled in seven patients. The median age at trans-
plantation was 20.2 years (range: 18.1-27.2). Majority (9/10)
underwent reduced-intensity conditioning (RIC) regimen
consisting of alemtuzumab, ﬂudarabine, and melphalan. One
underwent myeloablative preparative regimen consisting of
busulfan, cyclophosphamide, and ATG. Nine patients
received transplants fromHLA-matched donors (8-MUD and
1 MSD). Bone marrow was the source of stem cell in seven
patients and PBSC in another three. In most patients (9/10)
cyclosporine and prednisone was used as GvHD prophylaxis.Result: Overall survival was 50% (5/10) at a median follow-
up of 17 months post-transplant (range: 6 -82). In patients
who received RIC the survival was 56% (5/9). The median
time for neutrophil engraftment was 11 days (range: 9-15).
Grade II to IV acute GvHD developed in two patients. Mixed
donor chimerism was noted in 33% (3/9) of patients who
received RIC. Of the ﬁve patients who died one died prior to
engraftment on day 9, and other on day 45, three other died
after day+ 100(range: 193 -324). The cause of death was
bacterial sepsis with multi-organ failure in three patients,
and acute gut GvHD with intestinal perforation and candi-
demia in one, and progressive necrotizing leukoencephal-
opathy in another. Of the surviving ﬁve patients, NK cell
function had normalized in all of them and none have
developed chronic GvHD.
Conclusion: Overall survival of 56% with RIC in young adults
with HLH is lower than the 88% survival reported in patients
less than 18 years of age from our center (P < .05). Prospec-
tive multicenter study is warranted to validate the present
ﬁnding, and also better identify the risk factors in adults to
improve HCT outcome for HLH.350
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The optimal treatment for relapsed acute promyelocytic
leukemia (APL) in pediatric patients is controversial. Allo-
geneic hematopoietic stem cell transplantation is an alter-
native for consolidation therapy for these patients, with
published event-free survival rates of 70-75%. We report
a pediatric patient with acute promyelocytic leukemia (APL)
who relapsed 28 months after cord blood transplantation
from her sibling and then successfully treated with bone
marrow transplantation from the same donor after rein-
duction. First relapse occurred at 2 years of age, 4 months
after induction therapy with ATRA, cytarabine and dauno-
rubicin, during consolidation with ATRA and adriamycin.
Sibling donor matched cord blood transplantation was
performed after successful reinduction with arsenic
trioxide, using myeloablative conditioning regimen with
busulfan and cyclophosphamide and cyclosporine for GVHD
prophylaxis. Second relapse was also treated with arsenic
trioxide, and matched sibling bone marrow transplant from
the same donor 32 months after the cord blood transplant,
using conditioning with TBI, cytarabine and cyclophospha-
mide and low level cyclosporine prophylaxis. Chronic skin
GVHD with moderate scleroderma has developed, currently
under control, and this patient is now with no evidence of
malignancy and persistent molecular remission at 40
months post-second transplantation, approximately 6 years
and 8 months from diagnosis. This case report demon-
strates the role of graft-versus-leukemia activity in APL and
vividly illustrates the role of different cell sources from
same donor in allogeneic transplantation for pediatric
patients.
